

CITATION REPORT

List of articles citing

Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity

DOI: 10.1161/01.cir.0000160359.49478.c2
Circulation, 2005, 111, 1601-10.

Source: <https://exaly.com/paper-pdf/39114252/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
292	Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. 2005 , 131, 561-78		34 ⁰
291	Phosphodiesterase 5A as a target in cardiac disease. 2005 , 9, 1097-100		1
290	Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. 2006 , 15, 733-42		26
289	Anthracycline cardiotoxicity. 2006 , 5, 791-809		97
288	Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. 2006 , 319, 1336-47		37
287	The ubiquitous role of nitric oxide in cardioprotection. <i>Journal of Molecular and Cellular Cardiology</i> , 2006 , 40, 16-23	5.8	356
286	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702		366
285	Synergistic effects of atorvastatin and sildenafil in cardioprotection--role of NO. <i>Cardiovascular Drugs and Therapy</i> , 2006 , 20, 5-8	3.9	5
284	The emerging role for type 5 phosphodiesterase inhibition in heart failure. 2006 , 3, 123-8		12
283	Cardiovascular effects of phosphodiesterase 5 inhibitors. 2006 , 12, 3485-94		45
282	Expression, distribution and regulation of phosphodiesterase 5. 2006 , 12, 3439-57		105
281	Sildenafil extends survival and graft function in a large animal lung transplantation model. 2006 , 29, 288-93		16
280	Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 291, H2680-91	5.2	67
279	Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. 2007 , 282, 32749-57		81
278	cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. <i>Circulation Research</i> , 2007 , 100, 1569-78	15.7	255
277	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H1398-406	5.2	129
276	Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 292, H342-7	5.2	55

275	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. 2007 , 19, 139-48		45
274	Phosphodiesterase type 5: expanding roles in cardiovascular regulation. <i>Circulation Research</i> , 2007 , 101, 1084-95	15.7	164
273	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. <i>Cardiology in Review</i> , 2007 , 15, 76-86	3.2	52
272	Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. <i>Journal of Molecular and Cellular Cardiology</i> , 2007 , 42, 453-8	5.8	105
271	Beneficial effects of carbon monoxide-releasing molecules on post-ischemic myocardial recovery. <i>Life Sciences</i> , 2007 , 80, 1619-26	6.8	45
270	Phosphodiesterases. 2007 , 919-957		4
269	Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 293, H3111-21	5.2	59
268	Phosphodiesterase regulation of nitric oxide signaling. 2007 , 75, 303-14		112
267	Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. <i>British Journal of Pharmacology</i> , 2007 , 150, 567-76	8.6	42
266	Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. <i>British Journal of Pharmacology</i> , 2007 , 150, 538-40	8.6	22
265	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. 2007 , 52, 990-1005		45
264	Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. <i>Cardiovascular Drugs and Therapy</i> , 2007 , 21, 171-94	3.9	61
263	Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. <i>Cardiovascular Drugs and Therapy</i> , 2007 , 21, 367-74	3.9	36
262	Nonurologic applications of phosphodiesterase type 5 inhibitors. 2007 , 4, 64-70		1
261	Sildenafil and phosphodiesterase-5 inhibitors for heart failure. 2008 , 5, 110-4		17
260	Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. 2008 , 25, 37-44		101
259	Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes. 2008 , 45, 1723-8		50
258	Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. 2008 , 20, 2231-6		74

257	Preclinical assessment of cardiac toxicity. 2008 , 13, 702-7		41
256	Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. <i>Journal of Cellular and Molecular Medicine</i> , 2008 , 12, 2651-64	5.6	66
255	Essential role of mitochondrial Ca ²⁺ -activated and ATP-sensitive K ⁺ channels in sildenafil-induced late cardioprotection. <i>Journal of Molecular and Cellular Cardiology</i> , 2008 , 44, 105-13	5.8	67
254	Anthracycline cardiotoxicity: from bench to bedside. 2008 , 26, 3777-84		348
253	Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. 2008 , 283, 29572-85		153
252	A mouse model for juvenile doxorubicin-induced cardiac dysfunction. 2008 , 64, 488-94		52
251	Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1alpha signaling. 2008 , 233, 1222-30		36
250	Fatty acids ameliorate doxorubicin-induced intracellular ca ²⁺ increase and apoptosis in rat cardiomyocytes. 2008 , 31, 809-15		20
249	Complications cardiaques des maladies malignes et de leurs traitements. 2008 , 3, 1-19		2
248	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H1398-H1406	5.2	90
247	The role of nitric oxide in myocardial repair and remodeling. <i>Antioxidants and Redox Signaling</i> , 2009 , 11, 1913-28	8.4	89
246	cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. 2009 , 330, 884-91		59
245	Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. 2009 , 82, 30-9		56
244	Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. 2009 , 30, 1863-72		46
243	Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. 2009 , 297, F362-70		90
242	Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. 2009 , 91, 629-35		64
241	Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. 2009 , 122, 216-38		273
240	Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond. 2009 , 124, 279-300		51

239	Cardiovascular effects of phosphodiesterase type 5 inhibitors. 2009 , 6, 658-74		38
238	Cardiomyocyte death in doxorubicin-induced cardiotoxicity. 2009 , 57, 435-45		270
237	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. 2009 , 30, 1-24		45
236	Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress. 2009 , 104, 192-7		34
235	Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. 2009 , 255, 72-9		73
234	Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. 2009 , 257, 137-43		61
233	Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. 2009 , 28, 676-82		40
232	Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. <i>International Journal of Cardiology</i> , 2009 , 135, 72-7	3.2	16
231	Cyclic GMP-hydrolyzing phosphodiesterases. 2009 , 367-408		28
230	Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. 2009 , 53, 207-15		124
229	cGMP: Generators, Effectors and Therapeutic Implications. 2009 ,		13
228	Sildenafil decreased cardiac cell apoptosis in diabetic mice: reduction of oxidative stress as a possible mechanism. <i>Canadian Journal of Physiology and Pharmacology</i> , 2009 , 87, 556-64	2.4	23
227	Pharmacologic prevention of anthracycline-induced cardiomyopathy. <i>Cardiology in Review</i> , 2009 , 17, 243-52	3.2	8
226	Phosphodiesterase 5 inhibitors: are they cardioprotective?. 2009 , 83, 204-12		29
225	PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. <i>Basic Research in Cardiology</i> , 2010 , 105, 337-47	11.8	80
224	Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. 2010 , 3, 507-15		38
223	Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. 2010 , 124, 349-60		47
222	Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil. 2010 , 39, 363-72		22

221	Adenosine A3 receptor-mediated cardioprotection against doxorubicin-induced mitochondrial damage. 2010 , 79, 180-7		21
220	Erectile function rehabilitation in the radical prostatectomy patient. 2010 , 7, 1687-98		85
219	Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension. 2010 , 64, 15-22		8
218	Testosterone and chronic sildenafil/tadalafil anti-apoptotic role in aged diabetic rats. 2010 , 22, 255-61		25
217	The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP. <i>Circulation Research</i> , 2010 , 107, 1164-6	15.7	13
216	Cardioprotective actions of cyclic GMP: lessons from genetic animal models. 2010 , 55, 453-8		3
215	A new boost from sildenafil. 2010 , 3, 1198-1198		
214	Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. 2010 , 334, 1023-30		80
213	Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. 2010 , 107, 18202-7		116
212	Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 298, H1832-41	5.2	48
211	Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198). 2010 , 335, 223-30		23
210	Doxorubicin cardiomyopathy. 2010 , 115, 155-62		648
209	Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. 2010 , 56, 2021-30		57
208	Regression of cardiac hypertrophy by cyclic guanosine monophosphate-dependent protein kinase signaling are myocytes active sources or mere beneficiaries?. 2010 , 56, 2031-2		
207	Cardiac side-effects of cancer chemotherapy. <i>International Journal of Cardiology</i> , 2010 , 144, 3-15	3.2	284
206	Pulmonary hypertension in heart failure. 2010 , 16, 461-74		63
205	Prolyl hydroxylase 3 interacts with Bcl-2 to regulate doxorubicin-induced apoptosis in H9c2 cells. 2010 , 401, 231-7		33
204	Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2010 , 48, 310-21	5.8	39

203	Selenium-mediated cardioprotection against adriamycin-induced mitochondrial damage. 2011 , 34, 199-207	21
202	Penile rehabilitation after prostate cancer treatment: outcomes and practical algorithm. 2011 , 38, 105-18	19
201	Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by improving mitochondrial function. 2011 , 57, 2181-9	71
200	Phosphodiesterases as Drug Targets. 2011 ,	20
199	Phosphodiesterase-5 Inhibitors in Protection Against Doxorubicin-Induced Cardiomyopathy. 2011 , 243-255	
198	Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. 2011 , 12, 2297-313	12
197	Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. 2011 , 43, 540-57	49
196	Phosphodiesterase inhibition in heart failure. 2011 , 237-49	27
195	miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. 2011 , 17, 71-8	446
194	Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. <i>PLoS ONE</i> , 2011 , 6, e27910	3-7 20
193	Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect. 2011 , 2011, 350-355	
192	PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study. 2011 , 2011, 323-325	
191	Chronic vardenafil treatment improves erectile function via structural maintenance of penile corpora cavernosa in rats with acute arteriogenic erectile dysfunction. 2011 , 8, 705-11	19
190	Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. 2011 , 670, 541-53	23
189	Protection against adriamycin-induced cardiomyopathy by carnosine in rats: role of endogenous antioxidants. 2011 , 143, 412-24	17
188	Interfering with Smoking-Induced Pathophysiology. 2011 , 329-353	
187	Baicalein protects against doxorubicin-induced cardiotoxicity by attenuation of mitochondrial oxidant injury and JNK activation. 2011 , 112, 2873-81	61
186	Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. 2011 , 25, 600-12	256

185	Evidence for Pleiotropic Effects of Phosphodiesterase-5 (PDE5) Inhibitors: Emerging Concepts in Cancer and Cardiovascular Medicine. <i>Circulation Research</i> , 2011 , 108, 1040-1041	15.7	2
184	Res-erection of Viagra as a heart drug. 2011 , 4, 2-4		6
183	PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. 2011 , 4, 8-17		298
182	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. 2011 , 91, 651-90		443
181	Protective effect of carnosine on adriamycin-induced oxidative heart damage in rats. 2011 , 11, 3-10		25
180	Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. 2012 , 44, 766-75		22
179	Downregulation of doxorubicin-induced myocardial apoptosis accompanies postnatal heart maturation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 302, H1603-13	5.2	28
178	Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 302, H1347-54	5.2	55
177	Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. <i>Circulation</i> , 2012 , 125, 2323-33	16.7	129
176	Protein kinase g α inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. 2012 , 1, e003731		54
175	Heat shock factor-1 knockout induces multidrug resistance gene, MDR1b, and enhances P-glycoprotein (ABCB1)-based drug extrusion in the heart. 2012 , 109, 9023-8		33
174	Heat shock protein 25-enriched plasma transfusion preconditions the heart against doxorubicin-induced dilated cardiomyopathy in mice. 2012 , 341, 829-39		14
173	Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. <i>Circulation</i> , 2012 , 126, 2749-63	16.7	148
172	Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. <i>Circulation</i> , 2012 , 125, 1390-401	16.7	51
171	Phosphodiesterases and cyclic GMP regulation in heart muscle. 2012 , 27, 248-58		38
170	Cardiac uses of phosphodiesterase-5 inhibitors. 2012 , 59, 9-15		65
169	Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. <i>Basic Research in Cardiology</i> , 2012 , 107, 308	11.8	47
168	Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. 2012 , 26, 274-84		34

167	Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. <i>Journal of Molecular and Cellular Cardiology</i> , 2012 , 52, 1213-25	5.8	840
166	Effect of sildenafil on ventricular arrhythmias in post-infarcted rat hearts. 2012 , 690, 124-32		8
165	Protective effect of guggulsterone against cardiomyocyte injury induced by doxorubicin in vitro. 2012 , 12, 138		16
164	Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. 2012 , 8, 647-70		90
163	Detection and prevention of cardiac complications of cancer chemotherapy. 2012 , 105, 593-604		27
162	Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. 2012 , 59, 1921-7		58
161	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. 2012 , 9, 192-9		26
160	The cardioprotective effects of an antiemetic drug, tropisetron, on cardiomyopathy related to doxorubicin. <i>Cardiovascular Toxicology</i> , 2012 , 12, 318-25	3.4	14
159	Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. <i>PLoS ONE</i> , 2012 , 7, e45243	3.7	65
158	Autonomic cerebral vascular response to sildenafil in diabetic patient. 2012 , 4, 2		9
157	Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. 2012 , 30, 326-35		52
156	Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. <i>Basic Research in Cardiology</i> , 2012 , 107, 249	11.8	24
155	Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. 2012 , 292, 53-62		96
154	Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. 2013 , 10, 26-35		14
153	Sildenafil after cardiac arrest and infarction; an experimental rat model. 2013 , 47, 58-64		4
152	Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. 2013 , 60, 80-8		62
151	Therapeutic potential of PDE modulation in treating heart disease. 2013 , 5, 1607-20		24
150	Pulmonary hypertension associated with left heart disease. 2013 , 34, 665-80		11

149	Doxorubicin-Induced Cardiac Toxicity Is Mediated by Lowering of Peroxisome Proliferator-Activated Receptor α Expression in Rats. 2013 , 2013, 456042		15
148	Doxorubicin-induced vascular dysfunction and its attenuation by exercise preconditioning. <i>Journal of Cardiovascular Pharmacology</i> , 2013 , 62, 355-60	3.1	19
147	Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. <i>Journal of Cardiovascular Pharmacology</i> , 2013 , 62, 512-23 ^{3.1}		33
146	Effects of molsidomine against doxorubicin-induced cardiotoxicity in rats. 2013 , 51, 79-90		12
145	Doxorubicin caused apoptosis of mesenchymal stem cells via p38, JNK and p53 pathway. 2013 , 32, 1072-82		39
144	Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats. 2013 , 3, 84-7		14
143	Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects. 2013 , 6, 1268-83		19
142	Protective effect of melatonin against Adriamycin-induced cardiotoxicity. 2013 , 5, 1496-1500		12
141	Vascular Pharmacology. 2013 , 75-93		1
140	Sildenafil attenuates hepatocellular injury after liver ischemia reperfusion in rats: a preliminary study. <i>Oxidative Medicine and Cellular Longevity</i> , 2014 , 2014, 161942	6.7	20
139	Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways. <i>Oxidative Medicine and Cellular Longevity</i> , 2014 , 2014, 674219	6.7	55
138	PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. 2014 , 15, 758-67		41
137	Diabetic Cardiomyopathy. 2014 ,		2
136	Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction. 2014 , 11, 1101-15		28
135	Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. 2014 , 85, 408-19		56
134	Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. <i>Circulation Research</i> , 2014 , 115, 79-96	15.7	322
133	Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. 2014 , 88, 334-50		115
132	Clinical and molecular genetics of the phosphodiesterases (PDEs). 2014 , 35, 195-233		157

131	Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. 2014 , 35, 520-31		66
130	.		
129	The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review. 2015 , 12, 54		23
128	Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2015 , 65, 640-8	3.1	7
127	Anthracycline-Induced Cardiomyopathy in Adults. 2015 , 5, 1517-40		36
126	Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats. 2016 , 16, 234-41		33
125	Sildenafil Protects against Myocardial Ischemia-Reperfusion Injury Following Cardiac Arrest in a Porcine Model: Possible Role of the Renin-Angiotensin System. 2015 , 16, 27015-31		14
124	Redox regulation of cGMP-dependent protein kinase β in the cardiovascular system. <i>Frontiers in Pharmacology</i> , 2015 , 6, 139	5.6	18
123	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. 2015 , 2015, 138148		32
122	Near infra-red laser mediated photothermal and antitumor efficacy of doxorubicin conjugated gold nanorods with reduced cardiotoxicity in swiss albino mice. 2015 , 11, 1435-44		21
121	Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil. 2015 , 11, 177-89		5
120	Treatment of Chronic Right Heart Failure. 2015 , 401-418		
119	Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity. 2015 , 8, e001952		28
118	Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. 2015 , 89, 54-61		26
117	Boswellic acids synergize antitumor activity and protect against the cardiotoxicity of doxorubicin in mice bearing Ehrlich's carcinoma. <i>Canadian Journal of Physiology and Pharmacology</i> , 2015 , 93, 695-708	2.4	17
116	Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. 2015 , 36, 326-48		161
115	The effects of sildenafil and n-acetylcysteine on ischemia and reperfusion injury in gastrocnemius muscle and femoral artery endothelium. 2015 , 23, 21-30		9
114	Strategies to increase nitric oxide signalling in cardiovascular disease. 2015 , 14, 623-41		312

113	Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. 2015 , 20, 621-31		32
112	Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy. 2015 , 38, 597-604		8
111	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. 2015 , 147, 12-21		144
110	The Right Ventricle in Health and Disease. 2015 ,		4
109	Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II. 2016 , 68, 33-43		11
108	Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology. <i>Oxidative Medicine and Cellular Longevity</i> , 2016 , 2016, 4253169	6.7	8
107	Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. <i>Oncotarget</i> , 2016 , 7, 4399-413	3.3	29
106	Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17 Suppl 1, S55-63	1.9	8
105	Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G II Oxidation. 2016 , 291, 17427-36		34
104	Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases. 2016 , 59, 10411-10434		29
103	Preventing antineoplastic drug-related cardiomyopathy: old and new therapeutic strategies. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17 Suppl 1, S64-75	1.9	18
102	Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. 2016 , 111, 154-62		32
101	Pentoxifylline abrogates cardiotoxicity induced by the administration of a single high dose or multiple low doses of doxorubicin in rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2016 , 94, 1170-1177	2.4	1
100	The TGF- β pathway mediates doxorubicin effects on cardiac endothelial cells. <i>Journal of Molecular and Cellular Cardiology</i> , 2016 , 90, 129-38	5.8	14
99	Caspase-1 Inflammasome Activation Mediates Homocysteine-Induced Pyroptosis in Endothelial Cells. <i>Circulation Research</i> , 2016 , 118, 1525-39	15.7	122
98	MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes. 2016 , 90, 3087-3098		59
97	Chemical Endoplasmic Reticulum Chaperone Alleviates Doxorubicin-Induced Cardiac Dysfunction. <i>Circulation Research</i> , 2016 , 118, 798-809	15.7	60
96	Doxorubicin induced heart failure: Phenotype and molecular mechanisms. 2016 , 10, 17-24		155

95	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. 2016 , 39, 131-42		18
94	Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and EB Polyunsaturated Fatty Acids. 2016 , 40, 52-66		14
93	Rutin attenuates doxorubicin-induced cardiotoxicity via regulating autophagy and apoptosis. 2017 , 1863, 1904-1911		58
92	Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins. <i>Canadian Journal of Physiology and Pharmacology</i> , 2017 , 95, 295-304	2.4	7
91	Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 150	2.3	23
90	Sarcoma. 2017 ,		
89	Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase. <i>Journal of Cellular and Molecular Medicine</i> , 2017 , 21, 3277-3287	5.6	26
88	Chemotherapy for osteosarcoma: Adverse effects and remedial measures. <i>Pediatric Hematology Oncology Journal</i> , 2017 , 2, 41-47	0.3	3
87	A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases. <i>Biomedicine and Pharmacotherapy</i> , 2017 , 94, 541-556	7.5	25
86	Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational F-FDG PET/CT Observation. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1638-1645	8.0	42
85	Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice. <i>Antioxidants and Redox Signaling</i> , 2017 , 26, 153-164	8.4	11
84	Targeting the Cytoskeleton with Plant-Bioactive Compounds in Cancer Therapy. 2017 ,		2
83	Comparision of doxorubicin-induced cardiotoxicity in the ICR mice of different sources. <i>Laboratory Animal Research</i> , 2017 , 33, 165-170	1.9	17
82	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , 2017 , 8, 99179-99202	3.3	28
81	Macrophage migration inhibitory factor rescues mesenchymal stem cells from doxorubicin-induced senescence though the PI3K-Akt signaling pathway. <i>International Journal of Molecular Medicine</i> , 2018 , 41, 1127-1137	4.4	14
80	Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 315-323	1.9	19
79	Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. <i>British Journal of Pharmacology</i> , 2018 , 175, 223-231	8.6	21
78	CTRP3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of Sirt1. <i>Journal of Molecular and Cellular Cardiology</i> , 2018 , 114, 38-47	5.8	84

77	Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. <i>Cardio-Oncology</i> , 2018 , 4,	2.8	9
76	cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. <i>Basic Research in Cardiology</i> , 2018 , 113, 24	11.8	42
75	Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 245-253	3.9	12
74	Protective effects of magnesium sulfate against doxorubicin induced cardiotoxicity in rats. <i>Life Sciences</i> , 2018 , 207, 436-441	6.8	15
73	A Review on the Effect of Traditional Chinese Medicine Against Anthracycline-Induced Cardiac Toxicity. <i>Frontiers in Pharmacology</i> , 2018 , 9, 444	5.6	16
72	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. <i>Frontiers in Physiology</i> , 2018 , 9, 167	4.6	74
71	Roles of PDE1 in Pathological Cardiac Remodeling and Dysfunction. <i>Journal of Cardiovascular Development and Disease</i> , 2018 , 5,	4.2	9
70	Sildenafil ameliorates EAE by decreasing apoptosis in the spinal cord of C57BL/6 mice. <i>Journal of Neuroimmunology</i> , 2018 , 321, 125-137	3.5	17
69	Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy. <i>Science Advances</i> , 2019 , 5, eaaw6081	14.3	35
68	Boswellic acids ameliorate doxorubicin-induced nephrotoxicity in mice: a focus on antioxidant and antiapoptotic effects. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2019 , 6, 10-24	1.3	4
67	Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy. <i>Journal of Translational Medicine</i> , 2019 , 17, 229	8.5	10
66	Cross-talk between ER stress and mitochondrial pathway mediated adriamycin-induced testicular toxicity and DA-9401 modulate adriamycin-induced apoptosis in Sprague-Dawley rats. <i>Cancer Cell International</i> , 2019 , 19, 85	6.4	24
65	Cardiovascular Effects of Chemotherapy Used in the Treatment of Breast Cancers. <i>Cardiology in Review</i> , 2019 , 27, 87-96	3.2	6
64	Tadalafil: 15 years Journey in male erectile dysfunction and beyond. <i>Drug Development Research</i> , 2018 , 80, 683	5.1	8
63	N-Acetylcysteine potentiates the haemodynamic-improving effect of sildenafil in a rabbit model of acute pulmonary thromboembolism via the p38 MAPK pathway. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019 , 46, 163-172	3	8
62	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. <i>Antioxidants and Redox Signaling</i> , 2019 , 30, 2110-2153	8.4	73
61	FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT. <i>Cell Death and Differentiation</i> , 2020 , 27, 540-555	12.7	135
60	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020 , 177, 5467-5488	8.6	34

59	Effect of ghrelin on VEGF-B and connexin-43 in a rat model of doxorubicin-induced cardiomyopathy. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2019 , 31,	1.6	4
58	Maternal administration of tadalafil improves fetal ventricular systolic function in a Hey2 knockout mouse model of fetal heart failure. <i>International Journal of Cardiology</i> , 2020 , 302, 110-116	3.2	
57	cGMP Signaling and Modulation in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 75, 385-398	3.9	11
56	Effect of DC. on Apoptosis, Inflammation and Oxidative Stress Induced by Doxorubicin in Wistar Rats. <i>Plants</i> , 2020 , 9,	4.5	2
55	Bisoprolol and linagliptin ameliorated electrical and mechanical isometric myocardial contractions in doxorubicin-induced cardiomyopathy in rats. <i>Pharmacological Reports</i> , 2020 , 72, 867-876	3.9	2
54	PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications. <i>Endocrines</i> , 2020 , 1, 90-101	0.8	2
53	Pulmonary vascular resistance as a potential marker of reactive pulmonary hypertension reduction following sildenafil therapy in patients disqualified from orthotopic heart transplantation. <i>Advances in Medical Sciences</i> , 2020 , 65, 298-303	2.8	
52	Self-Maintenance of Cardiac Resident Reparative Macrophages Attenuates Doxorubicin-Induced Cardiomyopathy Through the SR-A1-c-Myc Axis. <i>Circulation Research</i> , 2020 , 127, 610-627	15.7	10
51	PDE5 inhibitor sildenafil attenuates cardiac microRNA 214 upregulation and pro-apoptotic signaling after chronic alcohol ingestion in mice. <i>Molecular and Cellular Biochemistry</i> , 2020 , 471, 189-201	4.2	1
50	Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020 , 1874, 188383	11.2	9
49	Estrogen Receptor-Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy. <i>JACC Basic To Translational Science</i> , 2020 , 5, 282-295	8.7	11
48	Osteocrin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity. <i>Clinical and Translational Medicine</i> , 2020 , 10, e124	5.7	59
47	The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. <i>Pharmacological Reviews</i> , 2020 , 72, 692-766	22.5	53
46	Regulatory Actions of Estrogen Receptor Signaling in the Cardiovascular System. <i>Frontiers in Endocrinology</i> , 2019 , 10, 909	5.7	17
45	Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity. <i>Antioxidants and Redox Signaling</i> , 2021 , 34, 572-588	8.4	4
44	Protective effects of gallic acid on doxorubicin-induced cardiotoxicity; an experimental study. <i>Archives of Physiology and Biochemistry</i> , 2021 , 127, 258-265	2.2	7
43	An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases. <i>Expert Opinion on Drug Discovery</i> , 2021 , 16, 183-196	6.2	3
42	Myocardial Impact of NHE1 Regulation by Sildenafil. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 617519	3.4	0

41	Protection against Doxorubicin-Induced Cardiotoxicity through Modulating iNOS/ARG 2 Balance by Electroacupuncture at PC6. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 6628957	6.7	3
40	Sildenafil in Combination Therapy against Cancer: A Literature Review. <i>Current Medicinal Chemistry</i> , 2021 , 28, 2248-2259	4.3	3
39	EPR-Effect Enhancers Strongly Potentiate Tumor-Targeted Delivery of Nanomedicines to Advanced Cancers: Further Extension to Enhancement of the Therapeutic Effect. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	7
38	Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 139, 111708	7.5	45
37	Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. <i>Cardio-Oncology</i> , 2021 , 7, 33	2.8	4
36	Sex Differences and Regulatory Actions of Estrogen in Cardiovascular System. <i>Frontiers in Physiology</i> , 2021 , 12, 738218	4.6	3
35	Serine mutations in overexpressed Hsp27 abrogate the protection against doxorubicin-induced p53-dependent cardiac apoptosis in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021 , 321, H963-H975	5.2	1
34	Cyclic nucleotide phosphodiesterase inhibition as a potential therapeutic target in renal ischemia reperfusion injury. <i>Life Sciences</i> , 2021 , 282, 119843	6.8	2
33	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. <i>Archivos De Cardiologia De Mexico</i> , 2015 , 85, 215-24	0.2	6
32	PDE5 inhibitor efficacy is estrogen dependent in female heart disease. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2464-71	15.9	49
31	Decreased autophagy in rat heart induced by anti- α -adrenergic receptor autoantibodies contributes to the decline in mitochondrial membrane potential. <i>PLoS ONE</i> , 2013 , 8, e81296	3.7	25
30	Disruption of ROCK1 gene restores autophagic flux and mitigates doxorubicin-induced cardiotoxicity. <i>Oncotarget</i> , 2018 , 9, 12995-13008	3.3	17
29	A Review on the Potential Benefits of Phosphodiesterase Inhibitors in Various Models of Toxicities in Animals. <i>Asian Journal of Animal and Veterinary Advances</i> , 2012 , 7, 210-224	0.1	3
28	Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond. <i>Annals of Translational Medicine</i> , 2016 , 4, 65	3.2	4
27	An experimental approach to study the function of mitochondria in cardiomyopathy. <i>BMB Reports</i> , 2015 , 48, 541-8	5.5	3
26	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
25	Apocynum venetum leaf extract alleviated doxorubicin-induced cardiotoxicity through the AKT/Bcl-2 signaling pathway. <i>Phytomedicine</i> , 2022 , 94, 153815	6.5	4
24	Erectile Function Preservation for Men with Cancer. 2011 , 657-673		

23	Phosphodiesterase-5 Inhibitors in Cardioprotection. 2013 , 439-458		
22	PDE-5 Inhibitors in Protection of Diabetic Heart. 2014 , 323-338		
21	Treatment Effects and Long-Term Management of Sarcoma Patients and Survivors. 2017 , 383-411		
20	Nitric oxide application for myocardial protection in coronary artery disease. <i>Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya</i> , 2019 , 34	0.4	
19	Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. <i>Molecular and Cellular Pharmacology</i> , 2010 , 2, 173-178		17
18	Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. <i>Experimental and Clinical Cardiology</i> , 2011 , 16, e30-5		39
17	Anthracycline-induced cardiomyopathy in a dog treated with epirubicin. <i>Canadian Veterinary Journal</i> , 2015 , 56, 571-4	0.5	5
16	Icariin Protects H9c2 Rat Cardiomyoblasts from Doxorubicin-Induced Cardiotoxicity: Role of Caveolin-1 Upregulation and Enhanced Autophagic Response. <i>Nutrients</i> , 2021 , 13,	6.7	0
15	Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches.. <i>Cardiovascular Toxicology</i> , 2022 , 22, 292	3.4	8
14	Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 812578	5.4	2
13	Sildenafil for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: A Phase I/II Randomized Clinical Trial, SILDAT-TAHA6 Trial.. <i>Cardiology Research and Practice</i> , 2022 , 2022, 5681510	1.9	
12	Saikosaponin D alleviates DOX-induced cardiac injury in vivo and in vitro.. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 79,	3.1	1
11	Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch.. <i>Redox Biology</i> , 2022 , 52, 102311	11.3	1
10	Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 847012	5.4	0
9	Novel Therapeutics for Anthracycline Induced Cardiotoxicity.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 863314	5.4	1
8	Saponins and their derivatives: potential candidates to alleviate anthracycline-induced cardiotoxicity and multidrug resistance. <i>Pharmacological Research</i> , 2022 , 106352	10.2	0
7	In vivo exposure to a new 2-cyano-2- p -nitrophenyl- N -benzylthioamide decreases doxorubicin-triggered structural damages in the mature testis.		0
6	Investigation of doxorubicin combined with ciprofloxacin-induced cardiotoxicity: from molecular mechanism to fundamental heart function.		0

- 5 GSK2795039 prevents RIP1-RIP3-MLKL-mediated cardiomyocyte necroptosis in doxorubicin-induced heart failure through inhibition of NADPH oxidase-derived oxidative stress. **2023**, 463, 116412 ○
- 4 Changes in Left Ventricular Ejection Fraction and Oxidative Stress after Phosphodiesterase Type-5 Inhibitor Treatment in an Experimental Model of Retrograde Rat Perfusion. **2023**, 59, 458 ○
- 3 Nitric Oxide-cGMP-PKG Signaling in the Cardioprotective Effects of Phosphodiesterase 5 Inhibitors. **2023**, 111-126 ○
- 2 Androgen-deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: effect of sildenafil. **2023**, 324, R589-R600 1
- 1 Nitric Oxide in Cardiac Surgery: A Review Article. **2023**, 11, 1085 ○